Pharmacologic comparison of clinical neutral endopeptidase inhibitors in a rat model of acute secretory diarrheas

David W. Griggs, Michael J. Prinsen, Jonathan Oliva, Mary A. Campbell, Stacy D. Arnett, Deena Tajfirouz, Peter G. Ruminski, Ying Yu, Brian R. Bond, Yuhua Ji, Georg Neckermann, Robert K.M. Choy, Eugenio De Hostos, Marvin J. Meyers

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Racecadotril (acetorphan) is a neutral endopeptidase (NEP) inhibitor with known antidiarrheal activity in animals and humans; however, in humans, it suffers from shortcomings that might be improved with newer drugs in this class that have progressed to the clinic for nonenteric disease indications. To identify potentially superior NEP inhibitors with immediate clinical utility for diarrhea treatment, we compared their efficacy and pharmacologic properties in a rat intestinal hypersecretion model. Racecadotril and seven other clinical-stage inhibitors of NEP were obtained or synthesized. Enzyme potency and specificity were compared using purified peptidases. Compounds were orally administered to rats before administration of castor oil to induce diarrhea. Stool weight was recorded over 4 hours. To assess other pharmacologic properties, select compounds were orally administered to normal or castor oil-treated rats, blood and tissue samples collected at multiple time points, and active compound concentrations determined by mass spectroscopy. NEP enzyme activity was measured in tissue homogenates. Three previously untested clinical NEP inhibitors delayed diarrhea onset and reduced total stool output, with little or no effect on intestinal motility assessed by the charcoal meal test. Each was shown to be a potent, highly specific inhibitor of NEP. Each exhibited greater suppression of NEP activity in intestinal and nonintestinal tissues than did racecadotril and sustained this inhibition longer. These results suggest that newer clinical-stage NEP inhibitors originally developed for other indications may be directly repositioned for treatment of acute secretory diarrhea and offer advantages over racecadotril, such as less frequent dosing and potentially improved efficacy.

Original languageEnglish
Pages (from-to)423-431
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume357
Issue number2
DOIs
StatePublished - May 2016
Externally publishedYes

Fingerprint Dive into the research topics of 'Pharmacologic comparison of clinical neutral endopeptidase inhibitors in a rat model of acute secretory diarrheas'. Together they form a unique fingerprint.

  • Cite this

    Griggs, D. W., Prinsen, M. J., Oliva, J., Campbell, M. A., Arnett, S. D., Tajfirouz, D., Ruminski, P. G., Yu, Y., Bond, B. R., Ji, Y., Neckermann, G., Choy, R. K. M., De Hostos, E., & Meyers, M. J. (2016). Pharmacologic comparison of clinical neutral endopeptidase inhibitors in a rat model of acute secretory diarrheas. Journal of Pharmacology and Experimental Therapeutics, 357(2), 423-431. https://doi.org/10.1124/jpet.115.231167